Cyclophosphamide (NCT07085728)

Name: Cyclophosphamide trial for Myeloma Multiple (NCT07085728)
Uploaded: 2026-10-31T16:46:54.209Z
Duration: 1 min 27 s
Description: Cyclophosphamide trial for Myeloma Multiple (NCT07085728). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07085728.

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure: a one-minute explainerNCT070857281 min

Cyclophosphamide trial for Myeloma Multiple (NCT07085728). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with newly diagnosed multiple myeloma and recent kidney failure from light-chain cast nephropathy. Up to one initial treatment cycle is allowed; prior anti-CD38 antibodies are excluded.

The idea: replace cyclophosphamide with daratumumab-hyaluronidase while retaining bortezomib and dexamethasone. Daratumumab targets CD38 to help kill myeloma cells. Random assignment selects either combination for four monthly cycles. Researchers assess kidney recovery, myeloma response and side effects. Dialysis does not automatically exclude participation.

This phase 2 study plans 74 patients. ECOG-ACRIN’s Amany Keruakous leads it; Anchorage is the single recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.